QQQ   444.85 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
QQQ   444.85 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
QQQ   444.85 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
QQQ   444.85 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)

Immunovant (IMVT) Stock Price, News & Analysis

$31.97
-0.55 (-1.69%)
(As of 03:16 PM ET)
Today's Range
$31.53
$32.95
50-Day Range
$30.27
$40.54
52-Week Range
$14.05
$45.58
Volume
600,140 shs
Average Volume
1.26 million shs
Market Capitalization
$4.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.88

Immunovant MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
50.7% Upside
$48.00 Price Target
Short Interest
Bearish
15.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.74mentions of Immunovant in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$659,896 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.70) to ($1.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.54 out of 5 stars

Medical Sector

479th out of 939 stocks

Biological Products, Except Diagnostic Industry

73rd out of 154 stocks

IMVT stock logo

About Immunovant Stock (NASDAQ:IMVT)

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

IMVT Stock Price History

IMVT Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Immunovant Awarded U.S. Patent for IMVT-1402
IMVT Jul 2024 30.000 call
Buy Friday, Sell Monday, No Exceptions
Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.
IMVT Mar 2024 40.000 call
IMVT Mar 2024 32.000 call
IMVT Apr 2024 45.000 put
IMVT Jan 2025 12.500 put
IMVT Mar 2024 29.000 put
IMVT Mar 2024 37.500 put
IMVT Mar 2024 37.000 call
IMVT Mar 2024 32.000 put
IMVT Mar 2024 33.000 put
IMVT Mar 2024 36.000 call
Immunovant Inc CFO Eva Barnett Sells 2,930 Shares
See More Headlines
Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/12/2024
Today
3/28/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
5/27/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IMVT
Fax
N/A
Employees
164
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$47.88
High Stock Price Target
$57.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+48.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
16 Analysts

Profitability

Net Income
$-210,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.78 per share

Miscellaneous

Free Float
138,319,000
Market Cap
$4.68 billion
Optionable
Optionable
Beta
0.67
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

IMVT Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunovant stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMVT shares.
View IMVT analyst ratings
or view top-rated stocks.

What is Immunovant's stock price target for 2024?

17 Wall Street analysts have issued 12-month price objectives for Immunovant's stock. Their IMVT share price targets range from $32.00 to $57.00. On average, they predict the company's share price to reach $48.00 in the next year. This suggests a possible upside of 50.7% from the stock's current price.
View analysts price targets for IMVT
or view top-rated stocks among Wall Street analysts.

How have IMVT shares performed in 2024?

Immunovant's stock was trading at $42.13 at the beginning of 2024. Since then, IMVT stock has decreased by 24.4% and is now trading at $31.85.
View the best growth stocks for 2024 here
.

Are investors shorting Immunovant?

Immunovant saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 9,350,000 shares, an increase of 7.7% from the February 29th total of 8,680,000 shares. Based on an average trading volume of 1,320,000 shares, the short-interest ratio is currently 7.1 days. Currently, 15.3% of the shares of the company are short sold.
View Immunovant's Short Interest
.

When is Immunovant's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024.
View our IMVT earnings forecast
.

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) released its quarterly earnings data on Monday, February, 12th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07.

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).

Who are Immunovant's major shareholders?

Immunovant's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.03%), Vanguard Group Inc. (4.01%), Point72 Asset Management L.P. (1.84%), Perceptive Advisors LLC (1.60%), Price T Rowe Associates Inc. MD (1.11%) and Price T Rowe Associates Inc. MD (1.10%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Julia G Butchko, Mark S Levine, Peter Salzmann, Sciences Ltd Roivant and William L Macias.
View institutional ownership trends
.

How do I buy shares of Immunovant?

Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMVT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners